273 related articles for article (PubMed ID: 23095041)
1. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
Fish PV; Filippakopoulos P; Bish G; Brennan PE; Bunnage ME; Cook AS; Federov O; Gerstenberger BS; Jones H; Knapp S; Marsden B; Nocka K; Owen DR; Philpott M; Picaud S; Primiano MJ; Ralph MJ; Sciammetta N; Trzupek JD
J Med Chem; 2012 Nov; 55(22):9831-7. PubMed ID: 23095041
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.
Gerstenberger BS; Trzupek JD; Tallant C; Fedorov O; Filippakopoulos P; Brennan PE; Fedele V; Martin S; Picaud S; Rogers C; Parikh M; Taylor A; Samas B; O'Mahony A; Berg E; Pallares G; Torrey AD; Treiber DK; Samardjiev IJ; Nasipak BT; Padilla-Benavides T; Wu Q; Imbalzano AN; Nickerson JA; Bunnage ME; Müller S; Knapp S; Owen DR
J Med Chem; 2016 May; 59(10):4800-11. PubMed ID: 27115555
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Benzo[
Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
[TBL] [Abstract][Full Text] [Related]
4. Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
Bamborough P; Diallo H; Goodacre JD; Gordon L; Lewis A; Seal JT; Wilson DM; Woodrow MD; Chung CW
J Med Chem; 2012 Jan; 55(2):587-96. PubMed ID: 22136469
[TBL] [Abstract][Full Text] [Related]
5. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
7. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
[TBL] [Abstract][Full Text] [Related]
8. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of BET bromodomains.
Filippakopoulos P; Qi J; Picaud S; Shen Y; Smith WB; Fedorov O; Morse EM; Keates T; Hickman TT; Felletar I; Philpott M; Munro S; McKeown MR; Wang Y; Christie AL; West N; Cameron MJ; Schwartz B; Heightman TD; La Thangue N; French CA; Wiest O; Kung AL; Knapp S; Bradner JE
Nature; 2010 Dec; 468(7327):1067-73. PubMed ID: 20871596
[TBL] [Abstract][Full Text] [Related]
10. Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.
Baud MGJ; Lin-Shiao E; Cardote T; Tallant C; Pschibul A; Chan KH; Zengerle M; Garcia JR; Kwan TT; Ferguson FM; Ciulli A
Science; 2014 Oct; 346(6209):638-641. PubMed ID: 25323695
[TBL] [Abstract][Full Text] [Related]
11. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
Picaud S; Da Costa D; Thanasopoulou A; Filippakopoulos P; Fish PV; Philpott M; Fedorov O; Brennan P; Bunnage ME; Owen DR; Bradner JE; Taniere P; O'Sullivan B; Müller S; Schwaller J; Stankovic T; Knapp S
Cancer Res; 2013 Jun; 73(11):3336-46. PubMed ID: 23576556
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 8-Methyl-pyrrolo[1,2-
Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
[TBL] [Abstract][Full Text] [Related]
13. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
[TBL] [Abstract][Full Text] [Related]
14. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
Chung CW; Dean AW; Woolven JM; Bamborough P
J Med Chem; 2012 Jan; 55(2):576-86. PubMed ID: 22136404
[TBL] [Abstract][Full Text] [Related]
15. Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex.
Sutherell CL; Tallant C; Monteiro OP; Yapp C; Fuchs JE; Fedorov O; Siejka P; Müller S; Knapp S; Brenton JD; Brennan PE; Ley SV
J Med Chem; 2016 May; 59(10):5095-101. PubMed ID: 27119626
[TBL] [Abstract][Full Text] [Related]
16. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
Hewings DS; Fedorov O; Filippakopoulos P; Martin S; Picaud S; Tumber A; Wells C; Olcina MM; Freeman K; Gill A; Ritchie AJ; Sheppard DW; Russell AJ; Hammond EM; Knapp S; Brennan PE; Conway SJ
J Med Chem; 2013 Apr; 56(8):3217-27. PubMed ID: 23517011
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode.
Lucas SCC; Atkinson SJ; Bamborough P; Barnett H; Chung CW; Gordon L; Mitchell DJ; Phillipou A; Prinjha RK; Sheppard RJ; Tomkinson NCO; Watson RJ; Demont EH
J Med Chem; 2020 May; 63(10):5212-5241. PubMed ID: 32321240
[TBL] [Abstract][Full Text] [Related]
19. Potent and selective bivalent inhibitors of BET bromodomains.
Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
[TBL] [Abstract][Full Text] [Related]
20. Naphthyridines as novel BET family bromodomain inhibitors.
Mirguet O; Lamotte Y; Chung CW; Bamborough P; Delannée D; Bouillot A; Gellibert F; Krysa G; Lewis A; Witherington J; Huet P; Dudit Y; Trottet L; Nicodeme E
ChemMedChem; 2014 Mar; 9(3):580-9. PubMed ID: 24000170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
